Population Pharmacokinetics of Intramuscular Quinine in Children with Severe Malaria
|
|
- Rafe Ramsey
- 5 years ago
- Views:
Transcription
1 ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Jun. 2001, p Vol. 45, No /01/$ DOI: /AAC Copyright 2001, American Society for Microbiology. All Rights Reserved. Population Pharmacokinetics of Intramuscular Quinine in Children with Severe Malaria SANJEEV KRISHNA, 1 * NELAMANGALA V. NAGARAJA, 2 TIM PLANCHE, 1 TSIRI AGBENYEGA, 3,4 GEORGE BEDO-ADDO, 4 DANIEL ANSONG, 4 ALEX OWUSU-OFORI, 4 ALBERT L. SHROADS, 5 GEORGE HENDERSON, 5 ALAN HUTSON, 6 HARTMUT DERENDORF, 2 AND PETER W. STACPOOLE 5,7 Department of Infectious Diseases, St. George s Hospital Medical School, Cranmer Terrace, London SW17 ORE, United Kingdom 1 ; Department of Physiology, University of Science and Technology, School of Medical Sciences, 3 and Departments of Paediatrics and Medicine, Komfo-Anokye Teaching Hospital, 4 Kumasi, Ghana; Department of Medicine (Division of Endocrinology and Metabolism), 5 Departments of Biochemistry and Molecular Biology, 7 and Department of Statistics (Division of Biostatistics), 6 University of Florida College of Medicine, Gainesville, Florida ; and Department of Pharmaceutics, University of Florida College of Pharmacy, Gainesville, Florida Received 7 September 2000/Returned for modification 10 February 2001/Accepted 13 March 2001 We present the first population pharmacokinetic analysis of quinine in patients with Plasmodium falciparum malaria. Ghanaian children (n 120; aged 12 months to 10 years) with severe malaria received an intramuscular loading dose of quinine dihydrochloride (20 mg/kg of body weight). A two-compartment model with first-order absorption and elimination gave post hoc estimates for pharmacokinetic parameters that were consistent with those derived from non-population pharmacokinetic studies (clearance [CL] 0.05 liter/h/kg of body weight; volume of distribution in the central compartment [V 1 ] 0.65 liter/kg; volume of distribution at steady state 1.41 liter/kg; half-life at phase 19.9 h). There were no covariates (including age, gender, acidemia, anemia, coma, parasitemia, or anticonvulsant use) that explained interpatient variability in weightnormalized CL and V 1. Intramuscular quinine was associated with minor, local toxicity in some patients (13 of 108; 12%), and 11 patients (10%) experienced one or more episodes of postadmission hypoglycemia. A loading dose of intramuscular quinine results in predictable population pharmacokinetic profiles in children with severe malaria and may be preferred to the intravenous route of administration in some circumstances. Although quinine is one of the oldest drugs in the pharmacopoeia, the optimum usage of quinine in children with severe malaria is still debated (12, 29). The choice of route and dose of quinine for children with severe malaria will vary depending on circumstances and particularly on the capability of administering intravenous infusions reliably. Quinine is the drug of choice for the management of severe malaria in most areas of the world, and it is frequently deployed in conditions where intravenous infusions cannot be rapidly established or reliably monitored. Recent pharmacokinetic studies using African children have revived the intramuscular route as an alternative, cheaper, practicable, and potentially safer route for quinine administration (15, 25, 27). However, classical pharmacokinetic studies are not always applicable to populations at highest risk of death from Plasmodium falciparum infection. One of the most important risk factors that identify these children is the complication of lactic acidosis (plasma or whole blood lactate concentration of 5 mmol/liter) (11). Dichloroacetate (DCA) is a potential treatment for malaria-associated lactic acidosis (7). We recently conducted a randomized, double-blind, placebo-controlled investigation to test the hypothesis that treatment with the lactate-lowering drug DCA, given with quinine, * Corresponding author. Mailing address: Department of Infectious Diseases, St. George s Hospital Medical School, Cranmer Terrace, London SW17 ORE, United Kingdom. Phone: Fax: s.krishna@sghms.ac.uk. significantly improved morbidity and mortality in Ghanaian children with lactic acidosis due to severe P. falciparum malaria infection. This report describes the population pharmacokinetics of a loading dose of intramuscular quinine dihydrochloride (20 mg/kg of body weight) in 120 patients. The size of this study also allows assessment of covariables that may be important in influencing quinine kinetics. The major clinical results of the study will be presented elsewhere. MATERIALS AND METHODS Patients. The study was carried out at the Komfo-Anokye Teaching Hospital in Kumasi, Ghana, and was approved by the Committee of Research, Publication and Ethics of the School of Medical Sciences, University of Science and Technology, Kumasi, Ghana, and the Institutional Review Board at the University of Florida. Between June 1997 and February 1999, 1,654 children with a suspected case of malaria were referred to the study team. Patients were examined by a member of the team, and samples were taken to measure glucose or lactate (100 l of whole blood or plasma), hematocrit, and parasitemia. After written, informed consent from parents or guardians was obtained, children were entered into this study if they fulfilled the following inclusion criteria: age of 12 months to 10 years inclusive, positive blood film for asexual stages of P. falciparum, and plasma venous or capillary blood lactate concentration of 5 mmol/liter. Exclusion criteria were pregnancy, assessed by a urine -human chorionic gonadotropin test in patients aged 10 years, and brain death, determined by clinical examination. Cerebral malaria was defined using the Blantyre Coma Score (BCS) ( 2 on a 5-point scale) (16). A lumbar puncture was performed on all patients with coma (BCS 2) to exclude the possibility of meningitis or encephalitis. The cerebrospinal fluid was analyzed immediately by microscopy and cultured. Quinine and DCA treatments. Quinine (20 mg/kg as a loading dose; diluted 1:1 [vol/vol] in water for injection, giving a final concentration for quinine dihydrochloride of 150 mg/ml) (Rotomed [Rotex, Trittau, Germany] or quinine 1803
2 1804 KRISHNA ET AL. ANTIMICROB. AGENTS CHEMOTHER. dihydrochloride [Martindale, Romford, United Kingdom]) was given to patients who had not received quinine treatment in the past 24 h. Half the loading dose was injected intramuscularly into the anterior aspect of each thigh. Maintenance doses of quinine (10 mg/kg, intramuscularly) were given into alternate thighs every 12 h (after dilution as before) until the patient was able to tolerate oral quinine. Patients were randomized to receive either DCA, 50 mg/kg formulated in 100 mg/ml as described previously (22), or normal saline (as placebo) after the first dose of quinine. DCA or placebo was given as a single infusion over 10 min by manual injection timed with a stopwatch. Supportive treatment. Patients were managed according to published guidelines (17), and supportive therapy included the following: (i) Correction of possible thiamine deficiency.to correct for a possible deficiency (10), all patients received a single intramuscular dose of thiamine (100 mg; Martindale) before DCA was administered. (ii) Prevention of hypoglycemia. A constant infusion of glucose (3 mg/kg/min, 5% dextrose) (Intravenous Infusions Ltd., Koforidua, Ghana) was administered to minimize the risk of hypoglycemia. Hypoglycemia (capillary or venous blood glucose concentration of 2.2 mmol/liter) was treated with a slow infusion of 50 or 25% glucose (1). (iii) Prevention and treatment of seizures. All patients with cerebral malaria received phenobarbitone (7 mg/kg, intramuscularly) (28), and seizures after admission were treated with diazepam (0.3 mg/kg, intravenously). (iv) Correction of anemia. A blood transfusion (20 ml/kg) was given to children with a hematocrit of 15%, and careful attention was given to maintenance of intravascular volume. Monitoring and sampling. Vital signs (respiratory rate, pulse, systolic and diastolic blood pressure, and temperature), BCS, hematocrit, glucose, and lactate were monitored every 4 h for 24 h after admission or more frequently, if clinically indicated. Venous blood samples (2 ml) were taken at baseline and at two time points between 0 and 12 h after the first DCA dose. Randomization of sampling times was done at 0, 10, 20, and 40 min and at 1, 2, 4, 8, and 12 h after DCA administration for collection of plasma to determine blood gas, metabolite, DCA, and quinine levels. As DCA was given a few minutes after quinine, this individual time difference for each patient was accounted for in analyses. Samples were collected in heparinized tubes (15 IU; Leo Pharmaceuticals, Risborough, United Kingdom). Plasma was separated within 15 min and stored and transported frozen ( 70 C) for analysis of quinine. Thick and thin blood films were also prepared at each pharmacokinetic time point and at every 4 h after admission, up to 24 h. Thereafter, sampling was performed every 6 h until parasitemia cleared. Analysis of quinine. Quinine was quantified in plasma samples by a previously reported high-performance liquid chromatography (HPLC) method (8). Briefly, plasma (100 l) was mixed with quinidine hydrochloride (10 l of a 200- g/ml solution), ammonia (60 l), and water (230 l). To this solution, methylene chloride (500 l) was added, and the mixture was vortexed (45 s). The two layers were separated by centrifugation (3,000 g, 10 min). The organic layer was vortex mixed with HCl (200 l, 0.15 M) and was centrifuged again. The upper aqueous layer was separated, and sample (5 l) was injected and analyzed by HPLC. HPLC was performed with a Hewlett-Packard 1100 Series system (Palo Alto, Calif.) made up of a G1322A Vacuum Degasser, a G1311A quaternary pump, a G1313A autosampler, and a G1315 diode array UV-visible detector. This instrument was coupled with a Hewlett-Packard Vectra Windows NT Workstation controlling pumps and detectors. A Hewlett-Packard Hypersil BDS-C-18 column (125 by 4 mm; inside diameter, 5 m) was used for isocratic chromatographic separation with a mobile phase consisting of acetonitrile and 1% triethylamine in water adjusted to ph 3 with o-phosphoric acid (15%:85% [vol/vol]). The flow rate was kept at 1 ml/min. Quinine and quinidine were detected at 254 nm, and retention times for quinine and quinidine were 5.2 and 4.5 min, respectively. The assay method was linear in the range of 2.5 to 40 g of quinine/ml. The inter- and intrabatch bias and relative standard deviation were 5% at all concentrations. Data analysis. (i) Pharmacostatistical model. Population modeling was developed by an expectation-and-maximization algorithm (described below) using P-Pharm software (InnaPhase, Champs sur Marne, France). Expectation-andmaximization analysis is an iterative two-step process suitable for computing maximum-likelihood (ML) population estimates of primary pharmacokinetic parameters. The algorithm computes the ML estimates by (i) an expectation step (E step), in which the individual parameters in the subjects are estimated by a Bayesian approach, given the present population parameters and the individual concentration-time data, and (ii) a maximization step (M step), in which the population parameters are estimated by ML methodology given the present individual-parameter estimates. These two steps are iterated up to convergence or until the fractional changes of fixed, random, and residual error variance parameters between two consecutive iterations become less than In the first stage, the population parameters and random effects (interindividual variations) together with the individual posterior estimates (Bayesian estimates) were computed with the assumption that no dependency exists between the pharmacokinetic parameters and the covariates. In the second stage, the relationship between the individual posterior estimates and the potential covariates was investigated by graphical exploratory functions and a multiple, linear, stepwise algorithm. Only those covariates showing a correlation with a pharmacokinetic parameter were retained in the analysis, and the population parameters were reestimated considering the ML ratio, Akaike information criterion (AIC), and residual distribution. Inspection of results and comparison with data from patients were used to assess the goodness of fit of the model. The two sites of quinine injection (10 mg/kg to each anterior thigh) were considered a single-depot compartment because the injections were administered almost simultaneously, and the bioavailability of intramuscular quinine was assumed to be complete (100%) (20). Demographic data and clinical admission and laboratory data were used as potential covariates to assess their relationship with derived population pharmacokinetic parameters for quinine. (ii) Model validation. The model was validated for standardized concentration prediction error (SCPE) and standardized parameter prediction error (SPPE) for clearance (CL), intercompartmental clearance (Q), volume of distribution in the central compartment (V 1 ), and volume of distribution in the peripheral compartment (V p ). SCPE for each concentration was calculated using the relationship: SCPE C obs C exp SD C exp ) C obs represents the observed concentrations, and SD (C exp ) represents the estimated standard deviation on the expected values computed, using all sources of random variability including residual error. For each pharmacokinetic parameter (CL and V 1 ), the normalized SPPEs were computed as SPPE P exp P pop SD P pop ) P pop is the population pharmacokinetic parameter, and SD (P pop ) is the corresponding standard deviation. To assess the posterior distribution properties of the residuals and the individual parameters, a t test was used to compare the mean of SCPE and SPPE to zero and the Kolmogorov-Smirnov test was used to compare the sampled distribution to the expected one [n (0,1)]. RESULTS Patients. Patients with malaria-associated lactic acidosis (n 124) were enrolled. Sixteen patients (12.9%) died, the majority of them (11 of 16; 69%) within 24 h of admission. Demographic, clinical admission, and laboratory features of patients are summarized in Table 1. All patients had one or more defining features of severe malaria, including hyperlactatemia, cerebral malaria (n 38; 31%), acidemia (39 of 81; 48%), or respiratory distress (n 67; 56%). Fifteen patients who did not have cerebral malaria on admission became comatose during the first 24 h of quinine treatment. Half the patients (n 62) were randomized to receive DCA. More detailed descriptions of these patients clinical courses will be published elsewhere. Ninety-two patients (74%) had a history of antimalarial treatment (1 with amodiaquine, 1 with artesunate, 10 with an unspecified antimalarial, and the remainder with chloroquine). Population modeling of quinine pharmacokinetics. Each patient contributed 1 to 3 plasma samples, depending on the actual time of blood sampling. Five patients with a history of prior quinine pretreatment had measurable baseline quinine levels. Three patients with baseline quinine levels above 2 g/ml (range, 6.6 to 13.4 g/ml) and one patient without measurable quinine levels for up to 1 h after admission were excluded from the population analysis. The patient without mea-
3 VOL. 45, 2001 POPULATION PHARMACOKINETICS OF QUININE 1805 TABLE 1. Demographic, admission, clinical, and laboratory data of study patients a Variable Result No. of patients Gender (male/female)... 72/52 Age (mo) Weight (kg) (6.6 24) Incidence of cerebral malaria (31%) Incidence of respiratory distress (56%) Use of diazepam (no/yes) b... 85/39 Use of phenobarbitone (no/yes) b... 82/42 Axillary temp ( C) ( ) Heart rate (min 1 ) Respiratory rate (breaths min 1 ) Systolic blood pressure (mm Hg) Diastolic blood pressure (mm Hg) Parasitemia (geometric mean [geometric SD]).. 157,860 (299,060) Hematocrit (%) (8 41.0) Lactate (mmol/liter) Glucose (mmol/liter) Venous ph No. with ph of /82 (48%) Venous po 2 (kpa) Venous pco 2 (kpa) a Data are means standard deviations. Ranges are included for some variables. b Administered on admission to this study. TABLE 2. Population and posterior estimates of pharmacokinetic parameters for quinine b Parameter Population estimate (CV, %) Result for Post hoc estimate (CV, %) CL (liter/h/kg) a 0.05 (73.6) 0.05 (18.9) V 1 (liter/kg) 0.65 (48.9) 0.65 (36.4) Q (liter/h/kg) 1.12 (47.6) 1.12 (15.4) V p (liter kg 1 ) (44.9) 0.76 (20.6) k a (h 1 ) 3.5 t 1/2ab (h) 0.2 V ss (liter/kg) (19.0) t 1/2 (h) (22.0) a Log normal distribution. b V ss, volume at steady state; t 1/2ab, absorption half-life; t 1/2, elimination halflife; k a is fixed at 3.5. CV, intersubject variability. No covariates. FIG. 1. (a) Population pharmacokinetic profile with 95% confidence intervals for quinine after a single intramuscular dose (20 mg/ kg). (b) Correlation between the observed quinine plasma levels and the Bayesian estimates predicted by the model. surable quinine survived. Another surviving patient s quinine concentration was 60 g/ml (0.5-h sample), and this time point was also excluded from analysis. Plasma samples (n 282) from 120 patients were available for population pharmacokinetic analysis of quinine. Based on earlier analysis and published reports (12), a two-compartment model with firstorder absorption and elimination was used to develop a population pharmacokinetic model for quinine. Total CL, Q, V 1, V p, and absorption rate constant (k a ) were used as the model parameters. The parameter k a was fixed at 3.5/h (absorption half-life of 12 min) (8) to arrive at reliable estimates of CL and V 1. Intersubject variability in CL had a log-normal distribution, while the values for intersubject variability for Q, V 1, and V p showed normal distributions. The distribution of residual errors was best explained by a multiplicative (proportional to the observed concentration) error model. The population mean and post hoc estimates of pharmacokinetic parameters are summarized in Table 2. Figure 1a displays the base population pharmacokinetic model fitted to 282 samples obtained from patients in this study and the correlation between observed plasma quinine levels and Bayesian estimates predicted by the model. Six values for quinine lie at or above 30 g/ml. These plasma samples were reassayed, and the initial measurements were confirmed. All these patients survived. The mean ( standard deviation) terminal elimination half-life for quinine was h. Figure 1b compares observed plasma quinine concentrations with those predicted from population modeling. When model validation was carried out (as detailed in Materials and Methods), results showed that the distributions of the residuals and the normalized parameters were normal and not significantly different from expected. These results are represented as histograms and cumulative distribution curves in Fig. 2.
4 1806 KRISHNA ET AL. ANTIMICROB. AGENTS CHEMOTHER. TABLE 3. Analysis of covariates for population pharmacokinetic parameters of quinine a,b Values for: Parameter Base model Covariate model FIG. 2. Histograms and cumulative distribution graphs for normalized residuals (A), CL (B), V 1 (C), Q (D), and V p (E). Mean CV Mean CV CL (liter/kg/h) V 1 (liter/kg) Q (liter/kg/h) V p (liter/kg) k a (h 1 ) t 1/2 (h) ML AIC Sigma y y a Sigma, residual variability; k a, fixed at 3.5; t 1/2, half-life at phase, estimated using post hoc parameters; y, observed concentration of quinine (Table 1); CV, intersubject variability. b Distribution models and equations: CL, log-normal distribution. CL weight sex age PCV cerebral DCA. V 1,Q,V p, normal distribution. V weight. Q PCV cerebral. V p cerebral DCA PCV. Analysis of covariates. Based on a preselected critical percentage (5%) of the F distribution to assess the contribution of a covariate in multiple, stepwise, linear regression, none of the following covariates influenced weight-normalized CL and V 1 : age, sex (0 male, 1 female), admission arterial ph, po 2, pco 2, body temperature, parasite count, cerebral malaria (0 no, 1 yes), phenobarbital treatment, diazepam treatment (0 no, 1 yes), and previous antimalarial treatment (0 no, 1 yes). When all of these factors were forcibly included as covariates and the data set was reanalyzed, weight, sex, age, hematocrit, and DCA (0 placebo, 1 DCA) treatment were selected as covariates for CL. Covariates for other parameters were weight for V 1 ; hematocrit and cerebral malaria for Q; and cerebral malaria, DCA, and hematocrit for V p. Intersubject variability estimates of all the parameters were lower with the covariate model (Table 3). However, there were no significant changes in the ML ratio and AIC. Analysis of the diagnostic graphs also did not indicate any improvements in the predictions. Hence, it was inferred that none of these patient-specific factors could be used reliably as covariables to explain interpatient variability in CL and V 1. Values for ph, po 2, and pco 2 were not available for 38 patients. The influence of these blood gas variables on the parameters was therefore assessed separately in a subgroup of 82 patients with all potential covariables. The base model parameters (without covariables) were similar to those for the data set containing 120 patients. In this subgroup also, none of these additional factors (ph, po 2, and pco 2 ) were selected as covariables. Hence, results from the complete data set with 120 patients were retained. Table 3 summarizes a model that includes covariates and goodness-of-fit parameters. There were no significant differences in estimates for pharmacokinetic parameters between survivors and fatal cases. Efficacy and tolerability of quinine. Figure 3a represents parasite CL data following quinine as a survival curve. The time taken for half the patients to clear parasites completely is 43 h. Figure 3b shows normalized parasite CL kinetics (median PC h and PC h, where PC 50 is the time taken for parasite numbers to fall by 50% of baseline values and PC 90 is the time required for parasite numbers to fall by 90% of baseline values). The median (interquartile range) parasite clearance time was 48 (36 to 54) h. Ninety-five (88%) patients from among 108 survivors had normal injection sites when discharged from the hospital. Twelve (11%) patients had mild, mainly unilateral induration, and one (1%) had unilateral swelling on discharge. Four (3%) of 68 patients who returned for follow-up examination 28 days after admission had evidence of local toxicity (two with induration and two with small [ 2 cm] fluctuant swellings). These patients were reexamined 1 to 2 weeks later, and local toxicity had resolved without specific therapy. It is not possible to attribute all local toxicity to quinine injections, as patients also received other intramuscular medication. Hypoglycemia (blood sugar level of 2.2 mmol/liter) was present in 19 (15%) patients prior to quinine treatment.
5 VOL. 45, 2001 POPULATION PHARMACOKINETICS OF QUININE 1807 FIG. 3. (a) Proportion of cases remaining positive for P. falciparum following admission. (b) Median change in parasitemia after admission. Numbers of patients contributing to each value are also given beside the data points. Eleven (10%) children had hypoglycemia following quinine treatment; four of these children also had admission hypoglycemia (relative risk for postadmission hypoglycemia was 3.2 [95% confidence interval 1.02 to 9.75; P 0.024], if there was preexisting hypoglycemia, when compared with patients who had no admission hypoglycemia). DISCUSSION Debate about the best way to administer quinine has continued since it was first used to treat severe malaria (12, 13, 29). Ross and others, working in India (14, 19), cautioned against using strong quinine solutions, because they might cause necrosis at the intramuscular injection site and might not be adequately absorbed. Diluted quinine was advocated as it was practically painless and rapidly effective (3). Fletcher provided a lucid review of clinical and laboratory experience on intramuscular quinine and suggested that it should be reserved for patients who are most dangerously ill with malaria (5). More recent studies have examined absorption of undiluted (300-mg/ml) (27) and diluted (150-mg/ml) (8) quinine and 60-mg/ml (18) quinine following a loading dose (20 mg of salt/kg). Dilution of quinine decreases the absorption half-life (mean standard deviation) from min to min (for 150-mg/ml quinine) and min (60-mg/ml quinine). There was no evidence of major local or systemic toxicity in these studies. A larger prospective evaluation of intramuscular (n 57) versus intravenous (n 47) quinine confirmed similar efficacy, safety, and blood levels of quinine for both routes (21) but did not include a pharmacokinetic analysis. Parasite CL estimates after quinine in our population are similar to those reported for children with cerebral malaria in The Gambia: median (with the interquartile range in parentheses) parasite CL time was 48 (36 to 54) h in our study, compared with 60 (48 to 72) h in the study from The Gambia (26). This study on the pharmacokinetics of intramuscular quinine in children with severe malaria exceeds other reports in size and detail. Population estimates for pharmacokinetic parameters presented here are consistent with previous, smaller, classical pharmacokinetic studies. For example, quinine CL is estimated here as equal to 0.05 liter/h/kg. In previous studies, estimates ranged from to liter/h/kg (reviewed in reference 12). In this study k a was fixed in order to obtain reliable estimates for other parameters. The suitability of distribution models is reflected in Fig. 1b, which shows the correlation between observed plasma concentrations of quinine and those predicted by Bayesian analysis. Quinine (20 mg/kg) is absorbed rapidly and reliably after dilution and intramuscular injection into both anterior thighs. Mean peak plasma concentration versus time profiles between 15 and 20 g/ml (Fig. 1a) are within the notional therapeutic range for quinine (12). The relatively broad confidence intervals around this value may reflect heterogeneity in quinine disposition rather than variability due to disease, as children were selected for study by strict and objective entry criteria and represent patients with the highest mortality (9, 11). The absence of any identifiable relationship between clinical and laboratory variables and population pharmacokinetic indices supports this suggestion. In particular, it is reassuring that intramuscular quinine is reliably absorbed, even in patients who may have severe acidemia, cerebral malaria, or anemia. Concomitant use of other medications (DCA, phenobarbital, and diazepam) also did not affect first-dose pharmacokinetics of quinine. Quinine is metabolized to 3-hydroxyquinine predominantly by the hepatic CYP4503A4 system (12). Since the expression of this enzyme system exhibits considerable interindividual variation (ranging from between 10 and 60% total hepatic cytochrome P450 activity) (6), genetic factors may contribute to quinine s variable disposition. There was no major local toxicity associated with our regimen of intramuscular quinine. Local side effects were selflimiting, and none required surgical intervention, in contrast to findings from The Gambia, where some children (5 of 288) (1.7%) given intramuscular quinine (diluted 1:5) needed drainage of abscesses (26). Patients who had hypoglycemia prior to admission were at highest risk of postadmission hypoglycemia, despite receiving a constant infusion of glucose (3 mg/kg/min). Taken together with observations on glucose kinetics in children with severe malaria receiving quinine (1), children who are hypoglycemic on admission to the hospital may require larger amounts of glucose (up to 6 mg/kg/min) than what we routinely used to
6 1808 KRISHNA ET AL. ANTIMICROB. AGENTS CHEMOTHER. transmitting blood-borne infections. The intravenous route incurs a risk of major quinine toxicity if infusion rates cannot be reliably managed. Thus, policies governing selection of one route over another must take into account these considerations. Our findings should increase confidence in the efficacy and safety of intramuscular quinine as the first choice for management of severe malaria in children. ACKNOWLEDGMENTS FIG. 4. Predicted pharmacokinetic profiles of four different doses of quinine based on population estimates: 20 mg/kg ( ), 10 mg/kg ( ), 15 mg/kg (- -), 20 mg/kg 10 mg/kg at 12 h ( - ). prevent hypoglycemia. In any case, this high-risk group should be monitored particularly carefully. These observations are consistent with studies in Kenyan children, where admission hypoglycemia (n 27 of 171; 16%) also identified children at risk of postadmission hypoglycemia (n 9; relative risk 5.33 [95% confidence interval 2.33 to 12.2; P ]). As in this study, some children who were euglycemic on admission subsequently developed hypoglycemia despite receiving dextrose (4). Postadmission rates of hypoglycemia were 15% in a large Gambian study (26). These observations contrast with those from Malawi indicating that glucose infusions prevented postadmission hypoglycemia after quinine treatment (23) and confirm that blood glucose should be monitored regularly, whenever practicable, in children with severe malaria. Figure 4 displays predicted quinine pharmacokinetic profiles of three different doses of quinine, based on our population analysis. Both 10- and 15-mg/kg doses are likely to undertreat a significant proportion of children in areas where parasites are not fully quinine sensitive. The safety of a 20-mg/kg loading dose of quinine and the potential for undertreatment suggest that this dose should be preferred in the management of severe malaria in African children. The risks of undertreatment with quinine were recently highlighted by a retrospective analysis that showed a significantly higher mortality rate in patients who received a 10-mg/kg dose than in those who received a 20-mg/kg dose of quinine (24). A few patients (5%) in our study had quinine levels of 30 g/ml, but none suffered toxicity. Only one patient had levels below 5 g/ml 12 h after the first dose of quinine. Many factors must be considered in choosing between intravenous and intramuscular routes for quinine use. Ease of administration, the lack of requirement for immediate intravenous access, more expensive fluid administration sets, predictable pharmacokinetics, usefulness in severe malaria, and safety favor the intramuscular route. However, the intramuscular route has some potential disadvantages, in particular the risk of infection (rarely tetanus or poliomyelitis) that may seed to areas of muscle necrosis (2, 5, 30). Both parenteral routes for quinine administration may be associated with hyperinsulinemic hypoglycemia and the risk of We thank Frank Micah, John Adabie Appiah, Cyclopea Anakwa, and Emmanuel Asafo-Agyei for patient care. Clement Opoku-Okrah and David Sambian gave technical support. We are grateful to Sister Esther Essuming and her staff for nursing care. This study was funded by National Institutes of Health award M to the General Clinical Research Center, University of Florida, and is part of a collaborative program for research in tropical medicine based at St. George s Hospital Medical School and funded by the Wellcome Trust. S.K. is a Wellcome Trust Senior Research Fellow in Clinical Science. REFERENCES 1. Agbenyega, T., B. Angus, G. Bedu-Addo, B. Baffoe-Bonnie, T. Guyton, P. Stacpoole, and S. Krishna Glucose and lactate kinetics in children with severe malaria. J. Clin. Endocrinol. Metab. 85: Barennes, H Intramuscular injections in sub-saharan African children, apropos of a frequently misunderstood pathology: the complications related to intramuscular quinine injections. Bull. Soc. Pathol. Exot. 92: (In French.) 3. Brodribb, C Quinine necrosis of muscle. Br. Med. J. ii: English, M., S. Wale, G. Binns, I. Mwangi, H. Sauerwein, and K. Marsh Hypoglycaemia on and after admission in Kenyan children with severe malaria. QJM 91: Fletcher, W Notes on the treatment of malaria with the alkaloids of cinchona, vol. 18. John Bale, Sons & Danielsson, Ltd., London, United Kingdom. 6. Gonzales, F. J., and J. R. Idle Pharmacogenetic phenotyping and genotyping. Clin. Pharmacokinet. 26: Holloway, P. A., K. Knox, N. Bajaj, D. Chapman, N. J. White, R. O Brien, P. W. Stacpoole, and S. Krishna Plasmodium berghei infection: dichloroacetate improves survival in rats with lactic acidosis. Exp. Parasitol. 80: Krishna, S., T. Agbenyega, B. J. Angus, G. Bedu-Addo, G. Ofori-Amanfo, G. Henderson, I. S. F. Szwandt, R. O Brien, and P. W. Stacpoole Pharmacokinetics and pharmacodynamics of dichloroacetate in children with lactic acidosis due to severe malaria. QJM 88: Krishna, S., W. Supanaranond, S. Pukrittayakamee, D. Karter, Y. Supputamongkol, T. M. E. Davis, P. A. Holloway, and N. J. White Dichloroacetate for lactic acidosis in severe malaria: a pharmacokinetic and pharmacodynamic assessment. Metabolism 43: Krishna, S., A. M. Taylor, W. Supanaranond, S. Pukrittayakamee, F. ter Kuile, K. M. Tawfiq, P. A. H. Holloway, and N. J. White Thiamine deficiency and malaria in adults from southeast Asia. Lancet 353: Krishna, S., D. Waller, F. ter Kuile, D. Kwiatkowski, J. Crawley, C. F. C. Craddock, F. Nosten, D. Chapman, D. Brewster, P. A. Holloway, and N. J. White Lactic acidosis and hypoglycaemia in children with severe malaria: pathophysiological and prognostic significance. Trans. R. Soc. Trop. Med. Hyg. 88: Krishna, S., and N. J. White Pharmacokinetics of quinine, chloroquine and amodiaquine. Clinical implications. Clin. Pharmacokinet. 30: Laveran, A Paludism, 1st. ed., vol. CXLVI. The New Sydenham Society, London, United Kingdom. 14. MacGilchrist, A. C Necrosis produced by intramuscular injections of strong solutions of quinine salts. Indian Med. Gaz. lii: Mansor, S. M., T. E. Taylor, C. S. McGrath, G. Edwards, S. A. Ward, J. J. Wirima, and M. E. Molyneux The safety and kinetics of intramuscular quinine in Malawian children with moderately severe falciparum malaria. Trans. R. Soc. Trop. Med. Hyg. 84: Molyneux, M. E., T. E. Taylor, J. J. Wirima, and A. Borgstein Clinical features and prognostic indicators in paediatric cerebral malaria: a study of 131 comatose Malawian children. QJM 265: Newton, C. W., and S. Krishna Severe falciparum malaria in children: current understanding of its pathophysiology and supportive treatment. Pharmacol. Ther. 79: Pasvol, G., C. R. J. C. Newton, P. A. Winstanley, W. M. Watkins, N. M. Peshu, J. B. O. Were, K. Marsh, and D. A. Warrell Quinine treatment
7 VOL. 45, 2001 POPULATION PHARMACOKINETICS OF QUININE 1809 of severe falciparum malaria in African children: a randomized comparison of three regimens. Am. J. Trop. Med. Hyg. 45: Ross, R Intramuscular injections of quinine. Lancet i: Shann, F., J. Stace, and M. Edstein Pharmacokinetics of quinine in children. J. Pediatr. 106: Shapira, A., T. Solomon, M. Julien, A. Macome, N. Parmar, I. Ruas, F. Simao, E. Streat, and B. Betschart Comparison of intramuscular and intravenous quinine for the treatment of severe and complicated malaria in children. Trans. R. Soc. Trop. Med. Hyg. 87: Stacpoole, P. W., E. C. Wright, T. G. Baumgartner, R. M. Bersin, S. Buchalter, S. H. Curry, C. A. Duncan, E. M. Harman, G. N. Henderson, S. Jenkinson, et al A controlled clinical trial of dichloracetate for treatment of lactic acidosis in adults. The Dichloroacetate-Lactic Acidosis Study Group. N. Engl. J. Med. 327: Taylor, T. E., M. E. Molyneux, J. J. Wirima, K. A. Fletcher, and K. Morris Blood glucose levels in Malawian children before and during the administration of intravenous quinine for severe falciparum malaria. N. Engl. J. Med. 319: van der Torn, M., P. E. Thuma, G. F. Mabeza, G. Biemba, V. M. Moyo, C. E. McLaren, G. M. Brittenham, and V. R. Gordeuk Loading dose of quinine in African children with cerebral malaria. Trans. R. Soc. Trop. Med. Hyg. 92: van Hensbroek, B. M., D. Kwiatkowski, B. van der Berg, F. J. Hoek, C. J. van Boxtel, and P. A. Kager Quinine pharmacokinetics in young children with severe malaria. Am. J. Trop. Med. Hyg. 54: van Hensbroek, B. M., E. Onyiorah, S. Jaffar, G. Schneider, A. Palmer, J. Frenkel, G. Enwere, S. Forck, A. Nusmeijer, S. Bennett, B. Greenwood, and D. Kwiatkowski A trial of artemether or quinine in children with cerebral malaria. N. Engl. J. Med. 335: Waller, D., S. Krishna, C. F. Craddock, D. Brewster, A. Jammeh, D. Kwiatkowski, J. Karbwang, P. Molunto, and N. J. White The pharmacokinetic properties of intramuscular quinine in Gambian children with severe falciparum malaria. Trans. R. Soc. Trop. Med. Hyg. 84: Waller, D., S. Krishna, J. Crawley, K. Miller, F. Nosten, D. Chapman, F. O. ter Kuile, C. F. Craddock, C. Berry, D. Brewster, B. M. Greenwood, and N. J. White The outcome and course of severe malaria in Gambian children. Clin. Infect. Dis. 21: White, N. J Controversies in the management of severe falciparum malaria, p In G. Pasvol (ed.), Malaria, vol. 2. Baillière Tindall, London, United Kingdom. 30. Yen, L. M., L. M. Dao, N. P. J. Day, D. J. Waller, D. B. Bethall, L. H. Son, T. T. Hien, and N. J. White Role of quinine in the high mortality of intramuscular injection tetanus. Lancet 344: Downloaded from on October 21, 2018 by guest
A comparative clinical trial of artemether and quinine in Cerebral Malaria
Original Article A comparative clinical trial of artemether and quinine in Cerebral Malaria Sheraz Jamal Khan, Syed Munib From Department of Medicine, Gomal Medical College, Dera Ismail Khan Correspondance:
More informationThe New England Journal of Medicine
The New England Journal of Medicine Copyright, 1996, by the Massachusetts Medical Society VOLUME 335 J ULY 11, 1996 NUMBER 2 A TRIAL OF ARTEMETHER OR QUININE IN CHILDREN WITH CEREBRAL MALARIA MICHAËL BOELE
More informationResidual neurologic sequelae after childhood cerebral malaria Boele van Hensbroek, M.; Palmer, A.; Jaffar, S.; Schneider, G.; Kwiatkowski, D.
UvA-DARE (Digital Academic Repository) Residual neurologic sequelae after childhood cerebral malaria Boele van Hensbroek, M.; Palmer, A.; Jaffar, S.; Schneider, G.; Kwiatkowski, D. Published in: The Journal
More informationRoutine anticonvulsants for treating cerebral malaria (Review)
Meremikwu MM, Marson AG This is a reprint of a Cochrane review, prepared and maintained by The Cochrane Collaboration and published in The Cochrane Library 2009, Issue 1 http://www.thecochranelibrary.com
More informationArtecef 50/Artecef 150 (ARTECEF BV) WHOPAR part 4 09/2008, version 1.0 MA027/028 SUMMARY OF PRODUCT CHARACTERISTICS. Page 1 of 7
SUMMARY OF PRODUCT CHARACTERISTICS Page 1 of 7 1. NAME OF THE MEDICINAL PRODUCT Artecef 50, Solution for intramuscular injection Artecef 150, Solution for intramuscular injection 2. QUALITATIVE AND QUANTITATIVE
More informationQuinine Pharmacokinetics and Pharmacodynamics in Children with Malaria Caused by Plasmodium falciparum
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Sept. 2005, p. 3658 3662 Vol. 49, No. 9 0066-4804/05/$08.00 0 doi:10.1128/aac.49.9.3658 3662.2005 Copyright 2005, American Society for Microbiology. All Rights Reserved.
More informationAntimalarials in the WHO Essential Drugs List for Children Reviewer No.1
Antimalarials in the WHO Essential Drugs List for Children Reviewer No.1 Part I: Evaluation of the current list Proposed grouping from the March 2007 meeting 6.5.3 Antimalarial medicines 6.5.3.1 For curative
More informationRespiratory problems with severe malaria: an opportunity to talk about fluid trials!!! Kathryn Maitland
Respiratory problems with severe malaria: an opportunity to talk about fluid trials!!! Kathryn Maitland Severe malaria-the numbers Up to 1 million deaths in African children
More informationRectal artesunate for pre-referral treatment of severe malaria
Global Malaria Programme Rectal artesunate for pre-referral treatment of severe malaria october 2017 information note Background Severe malaria is a medical emergency: mortality from untreated severe malaria
More informationFor personal use only
ASX Release Malaria 2012: Saving Lives in the Asia-Pacific Conference Update Eastland welcomes the commitment made by the Australian Government to save lives in the Asia Pacific region by pledging AU$100
More informationCLINICAL EXPERIENCE WITH INTRAVENOUS QUININE, INTRAMUSCULAR ARTEMETHER AND INTRAVENOUS ARTESUNATE FOR THE TREATMENT OF SEVERE MALARIA IN THAILAND
SOUTHEAST ASIAN J TROP MED PUBLIC HEALTH CLINICAL EXPERIENCE WITH INTRAVENOUS QUININE, INTRAMUSCULAR ARTEMETHER AND INTRAVENOUS ARTESUNATE FOR THE TREATMENT OF SEVERE MALARIA IN THAILAND Srivicha Krudsood
More informationSYNOPSIS. The study results and synopsis are supplied for informational purposes only.
SYNOPSIS INN : LEFLUNOMIDE Study number : HMR486/1037 et HMR486/3503 Study title : Population pharmacokinetics of A77 1726 (M1) after oral administration of leflunomide in pediatric subjects with polyarticular
More informationIntrasubject Variation in Elimination Half-Lives of Drugs Which Are Appreciably Metabolized
Journal of Pharmacokinetics and Biopharrnaceutics, Vol. 1, No. 2, 1973 SCIENTIFIC COMMENTARY Intrasubject Variation in Elimination Half-Lives of Drugs Which Are Appreciably Metabolized John G. Wagner 1
More informationOral Artesunate Dose-Response Relationship in Acute Falciparum Malaria
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Mar. 2002, p. 778 782 Vol. 46, No. 3 0066-4804/02/$04.00 0 DOI: 10.1128/AAC.46.3.778 782.2002 Copyright 2002, American Society for Microbiology. All Rights Reserved.
More informationA Simple Dose Regimen of Artesunate and Amodiaquine Based on Arm Span- or Age Range for Childhood Falciparum Malaria: A Preliminary Evaluation
JOURNAL OF TROPICAL PEDIATRICS, VOL. 58, NO. 4, 2012 A Simple Dose Regimen of Artesunate and Amodiaquine Based on Arm Span- or Age Range for Childhood Falciparum Malaria: A Preliminary Evaluation by Akintunde
More information38 Current Concepts in
38 Current Concepts in Management of Falciparum Malaria Abstract: Artemisinin based Combination Therapy (ACT) is the preferred agent to treat drug resistance uncomplicated Plasmodium Falciparum (PF) Malaria.
More informationSponsor: Sanofi Drug substance(s): SAR342434
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription. Sponsor: Sanofi Drug substance(s):
More informationKath Maitland Imperial College London & KEMRI / Wellcome Trust Programme, Kilifi, Kenya
Severe malaria: management with few resources Kath Maitland Imperial College London & KEMRI / Wellcome Trust Programme, Kilifi, Kenya Plasmodium falciparum malaria In African children
More information1. If the MTC is 100 ng/ml and the MEC is 0.12 ng/ml, which of the following dosing regimen(s) are in the therapeutic window?
Page 1 PHAR 750: Biopharmaceutics/Pharmacokinetics October 23, 2009 - Form 1 Name: Total 100 points Please choose the BEST answer of those provided. For numerical answers, choose none of the above if your
More informationDevelopment and Validation of RP-HPLC Method for the Simultaneous Estimation of Pyronaridine and Artesunate in Formulations
Human Journals Research Article February 2019 Vol.:14, Issue:3 All rights are reserved by N. Sunitha et al. Development and Validation of RP-HPLC Method for the Simultaneous Estimation of Pyronaridine
More informationArtemisinin Derivatives Versus Quinine for Severe Malaria in Children: A Systematic Review and Meta-Analysis
E U R E C A Artemisinin Derivatives Versus Quinine for Severe Malaria in Children: A Systematic Review and Meta-Analysis JOSEPH L MATHEW From the Advanced Pediatrics Centre, PGIMER, Chandigarh 160012,
More informationInteractions among primaquine, malaria infection and other
Br. J. clin. Pharmac. (1993), 35, 193-198 Interactions among primaquine, malaria infection and other antimalarials in Thai subjects G. EDWARDS" 2, C. S. McGRATH', S. A. WARD', W. SUPANARANOND3, S. PUKRITTAYAKAMEE3,
More informationBasic Concepts of TDM
TDM Lecture 1 5 th stage What is TDM? Basic Concepts of TDM Therapeutic drug monitoring (TDM) is a branch of clinical pharmacology that specializes in the measurement of medication concentrations in blood.
More informationBIOPHARMACEUTICS and CLINICAL PHARMACY
11 years papers covered BIOPHARMACEUTICS and CLINICAL PHARMACY IV B.Pharm II Semester, Andhra University Topics: Absorption Distribution Protein binding Metabolism Excretion Bioavailability Drug Interactions
More informationDECLINING MEFLOQUINE SENSITIVITY OF PLASMODIUM FALCIPARUM ALONG THE THAI-MYANMAR BORDER
SOUTHEAST ASIAN J TROP MED PUBLIC HEALTH DECLINING MEFLOQUINE SENSITIVITY OF PLASMODIUM FALCIPARUM ALONG THE THAI-MYANMAR BORDER Chaiporn Rojanawatsirivet 1, Kanungnit Congpuong 1, Saowanit Vijaykadga
More informationPDF hosted at the Radboud Repository of the Radboud University Nijmegen
PDF hosted at the Radboud Repository of the Radboud University Nijmegen This full text is a publisher's version. For additional information about this publication click this link. http://hdl.handle.net/2066/14779
More informationISSN X (Print) Original Research Article. DOI: /sjams India
DOI: 10.21276/sjams.2016.4.6.22 Scholars Journal of Applied Medical Sciences (SJAMS) Sch. J. App. Med. Sci., 2016; 4(6B):1981-198 5 Scholars Academic and Scientific Publisher (An International Publisher
More informationBASIC PHARMACOKINETICS
BASIC PHARMACOKINETICS MOHSEN A. HEDAYA CRC Press Taylor & Francis Croup Boca Raton London New York CRC Press is an imprint of the Taylor & Francis Group, an informa business Table of Contents Chapter
More informationAPPLICATION FOR REVISION AND INCLUSION OF MALARIA MEDICINES IN WHO MODEL LIST OF ESSENTIAL MEDICINES
APPLICATION FOR REVISION AND INCLUSION OF MALARIA MEDICINES IN WHO MODEL LIST OF ESSENTIAL MEDICINES The objective of this application is to assure compatibility between the WHO Model list of essential
More informationStatistical Analysis Plan (SAP)
Statistical Analysis Plan (SAP) Comparison of artemether-lumefantrine and chloroquine with and without primaquine for the treatment of Plasmodium vivax in Ethiopia: a randomized controlled trial Contents
More informationPFIZER INC. THERAPEUTIC AREA AND FDA APPROVED INDICATIONS: See USPI.
PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert. For publications based on this study, see associated bibliography.
More informationJ Pharm Sci Bioscientific Res (4): ISSN NO
Development and Validation of Analytical Methods for Simultaneous Estimation of Pregabalin and Amitriptyline Hydrochloride in their Combined Marketed Dosage form ABSTRACT: Nikhilkumar Patel, Gurjit Kaur,
More informationLactic Acidosis in Gabonese Children with Severe Malaria Is Unrelated to Dehydration
MAJOR ARTICLE Lactic Acidosis in Gabonese Children with Severe Malaria Is Unrelated to Dehydration J. N. Jarvis, 1,3,a T. Planche, 1,3,a T. Bicanic, 1,3 A. Dzeing-Ella, 2 M. Kombila, 2 S. Issifou, 3 S.
More informationSupplementary Online Content
Supplementary Online Content Dhabangi A, Ainomugisha B, Cserti-Gazdewich C, et al. Effect of transfusion of red blood cells with longer vs shorter storage duration on elevated blood lactate levels in children
More informationBasic Pharmacokinetic Principles Stephen P. Roush, Pharm.D. Clinical Coordinator, Department of Pharmacy
Basic Pharmacokinetic Principles Stephen P. Roush, Pharm.D. Clinical Coordinator, Department of Pharmacy I. General principles Applied pharmacokinetics - the process of using drug concentrations, pharmaco-kinetic
More informationJournal of Chemical and Pharmaceutical Research
Available on line www.jocpr.com Journal of Chemical and Pharmaceutical Research ISSN No: 0975-7384 CODEN(USA): JCPRC5 J. Chem. Pharm. Res., 2011, 3(2):770-775 Validation of Rapid Liquid Chromatographic
More informationCross-Matches for Bioequivalence Evaluation Division using Needle Free Jet Injector (Comfort-In) and conventional Pen type syringe.
Cross-Matches for Bioequivalence Evaluation Division using Needle Free Jet Injector (Comfort-In) and conventional Pen type syringe. Dr. EunJig, Lee http://www.yuhs.or.kr/en/hospitals/severance/clinic_dept/endo_dept/phy_directory/docprofile.asp?sno=1734
More informationNontraditional PharmD Program PRDO 7700 Pharmacokinetics Review Self-Assessment
Nontraditional PharmD Program PRDO 7700 Pharmacokinetics Review Self-Assessment Please consider the following questions. If you do not feel confident about the material being covered, then it is recommended
More informationManagement of malaria at Juba Teaching Hospital: a clinical audit
SSMJ Downloaded from www.southsudanmedicaljournal.com Management of malaria at Juba Teaching Hospital: a clinical audit David Attwood a MRCP and Stephen Raimon b MBBS Introduction Worldwide there are 247
More informationREVERSE PHASE HPLC METHOD FOR THE ANALYSIS OF ALFUZOSIN HYDROCHLORIDE IN PHARMACEUTICAL DOSAGE FORMS
Int. J. Chem. Sci.: 6(1), 2008, 399-404 REVERSE PHASE HPLC METHOD FOR THE ANALYSIS OF ALFUZOSIN HYDROCHLORIDE IN PHARMACEUTICAL DOSAGE FORMS S. APPALA RAJU, ARVIND B. KARADI and SHOBHA MANJUNATH HKES s
More informationAvailable online at Scholars Research Library
Available online at www.scholarsresearchlibrary.com Scholars Research Library Der Pharmacia Lettre, 2015, 7 (3):157-161 (http://scholarsresearchlibrary.com/archive.html) ISSN 0975-5071 USA CODEN: DPLEB4
More informationPharmacokinetics of Mefloquine Combined with Artesunate in Children with Acute Falciparum Malaria
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Feb. 1999, p. 341 346 Vol. 43, No. 2 0066-4804/99/$04.00 0 Copyright 1999, American Society for Microbiology. All Rights Reserved. Pharmacokinetics of Mefloquine
More informationFACTS. Approximately 2.48 million malaria cases are reported annually from South Asia. Of Which 75% cases are contributed by India alone.
MALARIA 2 FACTS Approximately 2.48 million malaria cases are reported annually from South Asia. Of Which 75% cases are contributed by India alone. The magnitude of the problem is further enhanced by P
More information*Sections or subsections omitted from the full prescribing information are not listed.
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use GIAPREZA TM safely and effectively. See full prescribing information for GIAPREZA. GIAPREZA (angiotensin
More informationArtesunate 60 mg for injection WHOPAR part 3 June 2013 (Guilin Pharmaceutical Co., Ltd.), MA051 PATIENT INFORMATION LEAFLET
PATIENT INFORMATION LEAFLET 1 PATIENT INFORMATION LEAFLET: INFORMATION FOR THE USER Artesun * Artesunate 60 mg for injection and sodium bicarbonate injection 50 mg/ml (1ml) and sodium chloride injection
More informationHospitalization Criteria in Imported Falciparum Malaria
306 Hospitalization Criteria in Imported Falciparum Malaria Valérie Briand, MD, MPH, * Olivier Bouchaud, MD, PhD, Jérôme Tourret, MD, Charlotte Behr, PhD, Sophie Abgrall, MD, PhD, Pascal Ralaimazava, MD,
More informationDISCUSSION DOSING AL 28/08/2007
DISCUSSION DOSING AL 28/08/2007 Following the WHO guidelines for the treatment of malaria (WHO, 2006, pages 23-24) the recommended dose for artemether/lumefantrine tablets (Coartem ) when used for children
More informationBioequivalence Studies of Two Formulations of Famciclovir Tablets by HPLC Method
Asian Journal of Chemistry Vol. 19, No. 6 (2007), 4245-4250 Bioequivalence Studies of Two Formulations of Famciclovir Tablets by HPLC Method K.V. SUBRAHMANYAM*, P. MOHANRAJ, P. SANDHYARANI, V.S. SARAVANAN
More informationSaliva Versus Plasma Bioequivalence of Rusovastatin in Humans: Validation of Class III Drugs of the Salivary Excretion Classification System
Drugs R D (2015) 15:79 83 DOI 10.1007/s40268-015-0080-1 ORIGINAL RESEARCH ARTICLE Saliva Versus Plasma Bioequivalence of Rusovastatin in Humans: Validation of Class III Drugs of the Salivary Excretion
More informationMalaria Updates. Fe Esperanza Espino Department of Parasitology Research Institute for Tropical Medicine
Malaria Updates Fe Esperanza Espino Department of Parasitology Research Institute for Tropical Medicine Outline General epidemiology of malaria in the Philippines P falciparum Updates in treatment Recognizing
More informationArtesunate 60 mg for injection WHOPAR part 3 November 2015 (Guilin Pharmaceutical Co., Ltd.), MA051 PATIENT INFORMATION LEAFLET
PATIENT INFORMATION LEAFLET 1 PATIENT INFORMATION LEAFLET: INFORMATION FOR THE USER Artesun 60mg * Artesunate 60 mg for injection and sodium bicarbonate injection 50 mg/ml (1ml) and sodium chloride injection
More informationPelagia Research Library
Available online at www.pelagiaresearchlibrary.com Der Pharmacia Sinica, 2015, 6(1):6-10 ISSN: 0976-8688 CODEN (USA): PSHIBD Validated RP-HPLC method for simultaneous estimation of metformin hydrochloride
More informationSection 5.2: Pharmacokinetic properties
Section 5.2: Pharmacokinetic properties SmPC training presentation Note: for full information refer to the European Commission s Guideline on summary of product characteristics (SmPC) SmPC Advisory Group
More informationAnkit et al Journal of Drug Delivery & Therapeutics; 2013, 3(2), Available online at RESEARCH ARTICLE
Ankit et al Journal of Drug Delivery & Therapeutics; 2013, 3(2), 26-30 26 Available online at http://jddtonline.info RESEARCH ARTICLE METHOD DEVELOPMENT AND ITS VALIDATION FOR QUANTITATIVE SIMULTANEOUS
More information9/02/10. Blood glucose and prognosis in children with presumed severe malaria: what is the threshold for hypoglycaemia? What is hypoglycaemia?
Context Blood glucose and prognosis in children with presumed severe malaria: what is the threshold for hypoglycaemia? Hubert Barennes 1, Moussa I. Dicko 2, Bertrand Graz 1, Mathieu Forster 4, Merlin L
More informationImpurity Profiling of Carbamazepine by HPLC/UV
Application Note: 52049 Impurity Profiling of Carbamazepine by HPLC/UV Terry Zhang, Guifeng Jiang, Thermo Fisher Scientific, San Jose, CA, USA Key Words Accela Hypersil GOLD Carbamazepine Drug Analysis
More informationSponsor / Company: Sanofi Drug substance(s): artesunate plus amodiaquine Title of the study:
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription. Sponsor / Company: Sanofi Drug substance(s):
More informationExtended Application Note
Extended Application Note Comparison of 4 μm vs. 2.o Columns in Analysis of Drospirenone/Ethinyl Estradiol Tablet APP A-339 www.mtc-usa.com 1-732-578-1777 INTRODUCTION The formulation of drospirenone and
More informationA COMPARATIVE STUDY OF QUININE V/S ARTESUNATE IN SEVERE MALARIA PATIENTS IN NORTHWESTERN RAJASTHAN, INDIA
A COMPARATIVE STUDY OF QUININE V/S ARTESUNATE IN SEVERE MALARIA PATIENTS IN NORTHWESTERN RAJASTHAN, INDIA K. C. Nayak, Rakesh Meena, *Surendra Kumar, B. K. Gupta, V. B. Singh and Varun Kulkarni Department
More informationPOPULATION PHARMACOKINETICS RAYMOND MILLER, D.Sc. Daiichi Sankyo Pharma Development
POPULATION PHARMACOKINETICS RAYMOND MILLER, D.Sc. Daiichi Sankyo Pharma Development Definition Population Pharmacokinetics Advantages/Disadvantages Objectives of Population Analyses Impact in Drug Development
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objective: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationIn several African countries in sub-saharan Africa, malaria is the leading cause of death in children under five.
TECHNICAL SEMINAR - MALARIA SLIDE 1 Technical Seminar - Malaria Malaria is an extremely important cause of mortality in different parts of world. In this technical seminar, I ll discuss the rationale for
More informationTHE PHARMACOKINETICS OF SINGLE DOSE VS STEADY-STATE DOSES OF PROPRANOLOL IN CIRRHOTIC MALAY PATIENTS
Malaysian Journal of Medical Sciences, Vol. 9, No. 1, January 2002 (16-20) ORIGINAL ARTICLE THE PHARMACOKINETICS OF SINGLE DOSE VS STEADY-STATE DOSES OF PROPRANOLOL IN CIRRHOTIC MALAY PATIENTS Zain-Hamid,
More informationISSN: ; CODEN ECJHAO E-Journal of Chemistry 2011, 8(3),
ISSN: 0973-4945; CODEN ECJHAO E- Chemistry http://www.e-journals.net 2011, 8(3), 1275-1279 Simultaneous Determination of Paracetamol, Phenylephrine Hydrochloride, Oxolamine Citrate and Chlorpheniramine
More informationDose-finding and efficacy study for i.m. artemotil (beta-arteether) and comparison with i.m. artemether in acute uncomplicated P. falciparum malaria
Dose-finding and efficacy study for i.m. artemotil (beta-arteether) and comparison with i.m. artemether in acute uncomplicated P. falciparum malaria S. Looareesuwan, 1 B. Oosterhuis, 2 B. M. Schilizzi,
More informationeven more potent than quinine (White, 1985), is also gaining wide use (Phillips et al., 1985). The binding of quinine and quinidine to
Br. J. clin. Pharmac. (1987), 24, 769-774 Differences in the binding of quinine and quinidine to plasma proteins GEORGE W. MIHALY, MICHAEL S. CHING, MARGARET B. KLEJN, JOHN PAULL' & RICHARD A. SMALLWOOD
More informationCombination Anti-malarial Therapy and WHO Recommendations
Prakaykaew Charunwatthana 2, and Sasithon Pukrittayakamee 1,2 1 Associate Fellow of the Royal Institute, Academy of Science 2 Department of Clinical Tropical Medicine, Faculty of Tropical Medicine, Mahidol
More informationThese results are supplied for informational purposes only.
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription Sponsor/company: sanofi-aventis ClinialTrials.gov
More informationAvailable online Research Article
Available online www.jocpr.com Journal of Chemical and Pharmaceutical Research, 2016, 8(1):171-176 Research Article ISSN : 0975-7384 CODEN(USA) : JCPRC5 Reverse phase high performance liquid chromatography
More informationPHARMACEUTICAL STABILITY OF PROMETHAZINE IN IV INFUSION FLUIDS Brittenham K, Choi R, Kapraly M, Kime B, Knoebel J
PHARMACEUTICAL STABILITY OF PROMETHAZINE IN IV INFUSION FLUIDS Brittenham K, Choi R, Kapraly M, Kime B, Knoebel J Statement of the Research Problem: There is insufficient data available concerning the
More informationMefloquine antimalarial prophylaxis in pregnancy: dose finding and pharmacokinetic study
Br. J. clin. Pharmac. (1990), 30, 79-85 Mefloquine antimalarial prophylaxis in pregnancy: dose finding and pharmacokinetic study F. NOSTEN', J. KARBWANG1, N. J. WHITE12, HONEYMOON', K. NA BANGCHANG', D.
More informationA HIGH PERFORMANCE LIQUID CHROMATOGRAPHIC ASSAY FOR LERCANIDIPINE HYDROCHLORIDE
Int. J. Chem. Sci.: 6(1), 2008, 441-446 A HIGH PERFORMANCE LIQUID CHROMATOGRAPHIC ASSAY FOR LERCANIDIPINE HYDROCHLORIDE S. APPALA RAJU, ARVIND B. KARADI and SHOBHA MANJUNATH HKES s College of Pharmacy,
More informationMALARIA CASE STUDY. Major Chris Carter Defence School of Healthcare Education, Department of Healthcare Education Birmingham City University
MALARIA CASE STUDY Major Chris Carter Defence School of Healthcare Education, Department of Healthcare Education Birmingham City University BACKGROUND Malaria is a parasitic infection caused by the genus
More informationCases of Severe Malaria and Cerebral Malaria in Apam Catholic Hospital and Manhiya District Hospital
Cases of Severe Malaria and Cerebral Malaria in Apam Catholic Hospital and Manhiya District Hospital CL Barba, MSIV Charles Drew University of Medicine and Science Los Angeles, CA QUESTION What pediatric
More informationFarmadol. Paracetamol 10 mg/ml INFUSION SOLUTION
Farmadol Paracetamol 10 mg/ml INFUSION SOLUTION Composition Each ml contains: Paracetamol 10 mg Pharmacology Pharmacodynamic properties The precise mechanism of the analgesic and antipyretic properties
More informationSimultaneous Estimation of Gemcitabine Hydrochloride and Capecitabine Hydrochloride in Combined Tablet Dosage Form by RP-HPLC Method
ISSN: 0973-4945; CODEN ECJHAO E- Chemistry http://www.e-journals.net 2011, 8(3), 1212-1217 Simultaneous Estimation of Gemcitabine Hydrochloride and Capecitabine Hydrochloride in Combined Tablet Dosage
More informationSeizure activity and neurological sequelae in Ugandan children who have survived an episode of cerebral malaria
Seizure activity and neurological sequelae in Ugandan children who have survived an episode of cerebral malaria Robert O Opoka 1, Paul Bangirana 2,3, Michael J Boivin 4, Chandy C. John 5, Justus Byarugaba
More informationMONITORING THE THERAPEUTIC EFFICACY OF ANTIMALARIALS AGAINST UNCOMPLICATED FALCIPARUM MALARIA IN THAILAND
SOUTHEAST ASIAN J TROP MED PUBLIC HEALTH MONITORING THE THERAPEUTIC EFFICACY OF ANTIMALARIALS AGAINST UNCOMPLICATED FALCIPARUM MALARIA IN THAILAND C Rojanawatsirivej 1, S Vijaykadga 1, I Amklad 1, P Wilairatna
More informationInternational Journal of Pharmaceutical Sciences and Drug Research 2018; 10(2): 85-94
Available online at www.ijpsdr.com International Journal of Pharmaceutical Sciences and Drug Research 2018; 10(2): 85-94 Research Article ISSN: 0975-248X CODEN (USA): IJPSPP Evaluation of Efficacy and
More informationF. Al-Rimawi* Faculty of Science and Technology, Al-Quds University, P.O. Box 20002, East Jerusalem. Abstract
JJC Jordan Journal of Chemistry Vol. 4 No.4, 2009, pp. 357-365 Development and Validation of Analytical Method for Fluconazole and Fluconazole Related Compounds (A, B, and C) in Capsule Formulations by
More informationDevelopment and Validation for Simultaneous Estimation of Sitagliptin and Metformin in Pharmaceutical Dosage Form using RP-HPLC Method
International Journal of PharmTech Research CODEN (USA): IJPRIF ISSN : 0974-4304 Vol.5, No.4, pp 1736-1744, Oct-Dec 2013 Development and Validation for Simultaneous Estimation of Sitagliptin and Metformin
More informationDr. M.Mothilal Assistant professor
Dr. M.Mothilal Assistant professor Bioavailability is a measurement of the rate and extent of drug that reaches the systemic circulation from a drug product or a dosage form. There are two different types
More informationProduct: Omecamtiv Mecarbil Clinical Study Report: Date: 02 April 2014 Page 1
Date: 02 April 2014 Page 1. 2. SYNOPSIS Name of Sponsor: Amgen Inc. Name of Finished Product: Omecamtiv mecarbil injection Name of Active Ingredient: Omecamtiv mecarbil (AMG 423) Title of Study: A double-blind,
More informationHPLC to UHPLC Transfer of USP Method for Amlodipine Besylate Using the Agilent 1290 Infinity II LC
HPLC to UHPLC Transfer of USP Method for Amlodipine Besylate Using the Agilent 129 Infinity II LC Application Note Small Molecule Pharmaceuticals Authors Gerd Vanhoenacker, Mieke Steenbeke, Koen Sandra,
More informationScholars Research Library. Der Pharmacia Lettre, 2015, 7 (5):44-49 (
Available online at www.scholarsresearchlibrary.com Scholars Research Library Der Pharmacia Lettre, 2015, 7 (5):44-49 (http://scholarsresearchlibrary.com/archive.html) ISSN 0975-5071 USA CODEN: DPLEB4
More informationHyderabad, India. Department of Pharmaceutical Chemistry, Glocal University, Saharanpur, India.
International Journal On Engineering Technology and Sciences IJETS RP-HPLC Method development and validation for the Simultaneous Estimation of Metformin and Empagliflozine in Tablet Dosage Form Shaik
More informationStudy on admitted cases of complicated malaria in Government General Hospital, Guntur
Original article: Study on admitted cases of complicated malaria in Government General Hospital, Guntur 1Dr. T. V. Adi Seshu Babu, 2 Dr.Uday Shankar Sanakayala 1Associate professor, Department of General
More informationDBL NALOXONE HYDROCHLORIDE INJECTION USP
Name of medicine Naloxone hydrochloride Data Sheet New Zealand DBL NALXNE HYDRCHLRIDE INJECTIN USP Presentation DBL Naloxone Hydrochloride Injection USP is a sterile, clear, colourless solution, free from
More informationDisclosure Information
Malaria Medications Charlie Mosler, RPh, PharmD, CGP, FASCP Assistant Professor of Pharmacy Practice The University of Findlay College of Pharmacy Findlay, OH mosler@findlay.edu Disclosure Information
More informationPOPULATION PHARMACOKINETICS
POPULATION PHARMACOKINETICS Raymond Miller, D.Sc. Daiichi Sankyo Pharma Development 1 Population Pharmacokinetics Definition Advantages/Disadvantages Objectives of Population Analyses Impact in Drug Development
More informationSIMULTANEOUS ESTIMATION OF VALSARTAN AND HYDROCHLOROTHIAZIDE IN TABLETS BY RP-HPLC METHOD
170 Original Article SIMULTANEOUS ESTIMATION OF VALSARTAN AND HYDROCHLOROTHIAZIDE IN TABLETS BY RP-HPLC METHOD *Lakshmana Rao A, 1 Bhaskara Raju V *V.V. Institute of Pharmaceutical Sciences, Gudlavalleru,
More informationHigh Postdischarge Morbidity in Ugandan Children With Severe Malarial Anemia or Cerebral Malaria
Journal of the Pediatric Infectious Diseases Society ORIGINAL ARTICLE High Postdischarge Morbidity in Ugandan Children With Severe Malarial Anemia or Cerebral Malaria Robert O. Opoka, 1 Karen E. S. Hamre,
More informationDecember 2012 Critical Care Case of the Month: Sepsis-like Syndrome in a Returning Traveler. Eric Chase, MD Eric Ong, MD John Bloom, MD
December 2012 Critical Care Case of the Month: Sepsis-like Syndrome in a Returning Traveler Eric Chase, MD Eric Ong, MD John Bloom, MD University of Arizona Division of Pulmonary and Critical Care Medicine
More informationScholars Research Library
Available online at www.scholarsresearchlibrary.com Scholars Research Library Der Pharmacia Lettre, 2010, 2(2): 294-299 (http://scholarsresearchlibrary.com/archive.html) ISSN 0975-5071 USA CODEN: DPLEB4
More informationMaximizing chromatographic peak capacity with the Agilent 1290 Infinity LC system
Maximizing chromatographic peak capacity with the Agilent 1290 Infinity LC system A practical guide on how to use parameters to increase peak capacity Application Note Pharmaceutical and Chemical Author
More informationLesson 6: Referal in severe and Complicated Malaria
Lesson 6: Referal in severe and Complicated Malaria From WikiEducator Contents 1 Introduction 1.1 Indications for Referral in Malaria 1.2 Criteria for Referral to Hospital 1.3 Management of Referred Patients
More informationKYAMC Journal Vol. 2, No.-2, January Bioequivalence study of Flunac and Diflucan in healthy Bangladeshi male volunteers
Original Article Bioequivalence study of Flunac and Diflucan in healthy Bangladeshi male volunteers Sarker UK 1, Misbahuddin M 2, Hossain MA 3. Abstract A bioequivalence study of a local antifungal drug,
More informationPHARMACOKINETICS OF DRUG ABSORPTION
Print Close Window Note: Large images and tables on this page may necessitate printing in landscape mode. Applied Biopharmaceutics & Pharmacokinetics > Chapter 7. Pharmacokinetics of Oral Absorption >
More informationMalaria in Injection Drug Abusers in Vietnam
MAJOR ARTICLE Malaria in Injection Drug Abusers in Vietnam T. T. H. Chau, 2 N. T. H. Mai, 2 N. H. Phu, 2 C. Luxemburger, 1,3 L. V. Chuong, 2 P. P. Loc, 2 T. T. M. Trang, 2 H. Vinh, 2 B. M. Cuong, 2 D.
More informationThe clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.
The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. Please note that the results reported in any single trial may not reflect the overall
More information